ISSN: 1354-3784

Journal Home

Journal Guideline

Expert Opinion on Investigational Drugs Q1 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Opinion on Investigational Drugs is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology with an H index of 117. It has a price of 4000 €. It has an SJR impact factor of 1,414 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,414.

Expert Opinion on Investigational Drugs focuses its scope in these topics and keywords: treatment, potential, therapeutic, development, drug, inhibitors, androgenetic, inhibitor, investigational, agonists, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Pharmacology (Q1) Pharmacology (medical) (Q1) Pharmacology (medical) (Q1)

Price

4000 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,414

SJR Impact factor

117

H Index

108

Total Docs (Last Year)

354

Total Docs (3 years)

8144

Total Refs

1698

Total Cites (3 years)

322

Citable Docs (3 years)

4.77

Cites/Doc (2 years)

75.41

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

New therapies and vaccines for bacterial meningitis

Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia

Peroxisome proliferator-activated receptor ligands in atherosclerosis

The future of obesity: new drugs versus lifestyle interventions

Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction

Ciclesonide: a novel inhaled corticosteroid

CT-2103: emerging utility and therapy for solid tumours

The therapeutic potential of monoclonal antibodies against respiratory syncytial virus

The therapeutic potential of Na+and Ca2+channel blockers in pain management

Apoptosis regulating proteins as targets of therapy for haematological malignancies

Platelet substitutes and novel platelet products

DNA minor groove binding ligands: a new class of anticancer agents

SHOW MORE ARTICLES

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

The potential of retro-inverso peptides as synthetic vaccines

Alzheimer?s disease - current trends in basic and clinical research. Highlights from the 16th ECNP

Experimental and emerging therapies for sepsis and septic shock

New strategies for the prevention and treatment of Helicobacter pylori infection

Erratum

Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease

Campylobacter vaccine development:a key to controlling enteric diseases

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

Addenda

New investigational antifungal agents for treating invasive fungal infections

Celecoxib for the treatment of atherosclerosis